OrbitonOpen research workspace →
Cardiol Therapeutics Inc. logo

Cardiol Therapeutics Inc.

TSX:CRDLLive AI agent

Cardiol Therapeutics is a late-stage life sciences company focused on advancing anti-inflammatory and anti-fibrotic therapies for heart disease.

Investor website: https://www.cardiolrx.com/

About

Cardiol Therapeutics is a late-stage life sciences company focused on advancing anti-inflammatory and anti-fibrotic therapies for heart disease. The company is dedicated to discovering novel therapeutic approaches that improve outcomes for patients suffering from underserved heart diseases, including pericarditis, myocarditis, and heart failure.

Verified company data

Cash position
$83.9M
Shares outstanding
115.88m
Fully diluted shares
not discovered
Mineral resource
not discovered
Projects
["Cardiol Therapeutics Announces First Patient Enrolled in Phase II Study Evaluating CardiolRx™ for the Treatment of Recurrent Pericarditis\n\n* * *\n\nThe Cleveland Clinic Recruits First Participant in the Multi-center U.S. Study\n\n**Oakville, ON** **–** **January 17,** **2023 –** Cardiol Therapeutics Inc. ( **NASDAQ: CRDL**) ( **TSX: CRDL**) ( **“** **Cardiol** **”** or the **“Company”**), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases, announced today that the first patient has been enrolled in the Company-sponsored Phase II open-label pilot study (NCT05494788) investigating the tolerance, safety, and efficacy of CardiolRx™ in patients with recurrent pericarditis. In addition to standard safety assessments, the study is designed to evaluate improvement in objective measures of disease, and during an extension period, assess the feasibility of weaning concomitant background therapy including corticosteroids, while taking CardiolRx™.\n\n“We are excited to be the first clinical center to administer this investigational drug in a patient with recurrent pericarditis, a debilitating inflammatory heart disease associated with symptoms that adversely affect quality of life and physical activity,” commented Dr. Paul C. Cremer, Cardiologist, Center for the Diagnosis and Treatment of Pericardial Diseases, Section of Cardiovascular Imaging, Department of Cardiovascular Medicine, Heart, Vascular, and Thoracic Institute, Cleveland Clinic and study site principal investigator. “Along with other collaborating research centers throughout the U.S., we look forward to full enrollment of participants into this pilot study and to determining the potential of this therapy to treat pericarditis and to reduce the risk of its recurrence.”\n\nThe Phase II pilot study is expected to enroll 25 patients at clinical centers in the United States that specialize in pericarditis care. The protocol has been designed in collaboration with thought leaders in pericardial disease. The study Chairman is Allan L. Klein, MD, Director of the Center of Pericardial Diseases and Professor of Medicine, Heart and Vascular Institute, at the Cleveland Clinic. The primary efficacy endpoint is the change, from baseline to 8 weeks, in patient-reported pericarditis pain using an 11-point numeric rating scale (“NRS”). The NRS is a validated clinical tool employed across multiple conditions with acute and chronic pain, including previous studies of recurrent pericarditis. Secondary endpoints include the pain score after 26 weeks of treatment, and changes in circulating levels of C-reactive protein, a commonly used clinical marker of inflammation.\n\nPre-clinical data adding to the strong scientific basis for investigating CardiolRx™ clinically in recurrent pericarditis were presented at the American Heart Association Scientific Sessions 2022. Cardiol’s research collaborators from Virginia Commonwealth University presented results demonstrating the protective effects of CardiolRx™ in a model of pericarditis, which included a significant reduction in imaging signs of pericardial effusion and thickening, and significant suppression of key pro-inflammatory markers interleukin-1β (“IL-1β”) and interleukin-6 (“IL-6”). The release of these cytokines IL-1β and IL-6 is responsible for the cycle of inflammation in recurrent pericarditis leading to the pericardial effusion and thickening characteristic of the disease."]
Leadership
David Elsley (CEO, Founder of Vasogen Inc., with extensive experience in biotechnology and management of clinical trials for heart failure therapies.), Andrew Hamer (Chief Medical Officer, Former Executive Director at Amgen Inc. with 19 years of cardiology practice and extensive clinical trial experience.), Chris Waddick (CFO, Former CFO at Vasogen Inc. with over 12 years of experience in biotechnology and corporate finance.), Guillermo Torre-Amione (Chief Scientific Officer, Professor of Cardiology with a focus on heart failure and cardiac transplant research, published over 170 manuscripts in peer-reviewed journals.)

Verified data last updated:

Recent filings

Investor FAQ